This is preliminary data from a combined Phase 2/3 clinical trial, so they are still confirming the dosing along with the tolerance, but the preliminary results from this Pfizer trial are even better than those from the Merck drug. Which suggests that COVID may soon be something that is survive-able for more people!
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study | Pfizer
PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19 In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 death…
An 89% reduction is AMAZING, and it will be good to see what the final analysis shows.
This warms my heart. We could all use some more hope for better outcomes with this terrible pandemic.